NEVVI Medicare utilization intelligence
Compare this code with others

Jump to the result views

G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms HCPCS · General Laboratory test
Classification Test › General Laboratory › Drug Tests (CMS RBCS)
First observed 2016
National scale 926,681 services · est. ▲ 5.8% YoY · 259,038 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 455,037 observed fee-for-service services
CMS descriptor · RBCS classification · Medicare Part B physician/supplier claims, 12-year window · National figures — the NC market is below
Data year CY2024 CY2023 CY2022 locked column CY2021 locked column CY2020 locked column
Filter results:
Market summary
Market Brief G0481
A shareable PDF report summarizing this market’s size, trends, and providers.
Preview this Brief →

This market's Overview — its estimated all-Medicare volume, national benchmarks, and what the field charges and is paid — is part of Explore.

See what Medicare pays

An Explore subscription, $249 a seat a year, opens the Overview on every code, group and clinician page, including what the market charges and is paid.

It comes with 25 credits a seat a year for Deep Dives, which open the rest.

Subscribe to Explore →

Included in Explore. Part of a Deep Dive.
Continue from here

Browse Medicare billing by specialty →